Please login to the form below

Not currently logged in
Email:
Password:

SGLT2

This page shows the latest SGLT2 news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... which as yet is the only

Latest news

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    The filing is based on the results of the CANVAS trial, which showed that its SGLT2 inhibitor Invokana (canagliflozin) was able to reduce the combined risk of cardiovascular death, myocardial infarction ... If the FDA approves the label, Invokana could

  • Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials

    Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials. Invokana cuts risk of heart failure hospitalisation by a third. ... Johnson &Johnson's SGLT2 inhibitor Invokana has become the second drug in the SGLT2 inhibitor class to reduce

  • Surging Trulicity takes sting out of Lilly's arthritis setback Surging Trulicity takes sting out of Lilly's arthritis setback

    There was somewhat disappointing news on SGLT2 inhibitor Jardiance (empagliflozin) for diabetes however, sales nearly doubled to $74m but that was well shy of expectations given the drug's impressive performance

  • FDA won't add outcomes data to Januvia label FDA won't add outcomes data to Januvia label

    The DPP-4 inhibitors as a class are facing stiffer competition from SGLT2 inhibitors - another class of type 2 diabetes drugs that have data indicating they can actually improve cardiovascular outcomes. ... The EMPA-REG OUTCOME trial showed that Eli

  • AZ data suggest SGLT2 inhibitors can reduce heart failure risk AZ data suggest SGLT2 inhibitors can reduce heart failure risk

    AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... SGLT2 inhibitors cut hospitalisations for heart failure by 39% and all-cause mortality by 51%

More from news
Approximately 8 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Figure 1 (pictured right) shows the position of the DPP4/SGLT2 market for the last four months to March 2017 in English GP practices compared to the previous Tertial (four months). ... In contrast Jardiance and Vipidia are still growing where Jardiance

  • Deal Watch November 2015 Deal Watch November 2015

    Sotagliflozin is an oral dual inhibitor of sodium-glucose cotransporters type 1 and 2 (SGLT1 &SGLT2) which are responsible for glucose reabsorption by the GI tract and kidney respectively.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J& J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. “ ... The potential for the SGLT2 class of treatments which Forxiga is the first to launch, is tremendous.”.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics